Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 115NIH 56NETWORK 9INDUSTRY 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Melanoma 33Skin Neoplasms 10Uveal Melanoma 7Neoplasms 3Carcinoma, Basal Cell 3Recurrence 2Lymphoma, T-Cell 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Uveal Neoplasms 1Ulcer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Skin Diseases 1Skin Cancer Face 1Sarcoma 1Parkinson Disease 1Pain 1Nevus 1Nevi and Melanomas 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mucosal Melanoma 1Margins of Excision 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Keratosis, Actinic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Immunoblastic Lymphadenopathy × Dermatologic × Clear all
NCT02533700 2020-03-10

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

Shandong Provincial Hospital

Phase 2 Unknown
106 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡